Kadimastem receives Hong Kong patent for diabetes therapy technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
September 4, 2025 7:38 AM EDTÂ Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and IndiaHong Kong represents a meaningful diabetes market and a critical gateway into Mainland Chinaincluding the Greater Bay Areasupporting future clinical collaboration, partnering and commercialization paths for... More
